UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of December 2025 (Report No. 2)
Commission
File Number: 001-42796
Nasus
Pharma Ltd.
Yigal
Alon 65
Tel
Aviv, Israel 6744317
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
CONTENTS
This
Report of Foreign Private Issuer on Form 6-K of Nasus Pharma Ltd. (the “Company”) consists of the Company’s: (i) Condensed
Unaudited Interim Financial Statements as of and for the six months ended June 30, 2025, which are attached as Exhibit 99.1 hereto; and
(ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the six months ended June
30, 2025, which is attached as Exhibit 99.2 hereto.
EXHIBIT
INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Condensed Unaudited Interim Financial Statements as of and for the Six Months Ended June 30, 2025. |
| 99.2 |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operation as of and for the Six Months Ended June 30, 2025. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
NASUS PHARMA LTD. |
| |
|
|
| Date: December 29, 2025 |
By: |
/s/ Dan
Teleman |
| |
Name: |
Dan Teleman |
| |
Title: |
Chief Executive Officer |
